Zhang Financial LLC Has $1.09 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Zhang Financial LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,404 shares of the biopharmaceutical company’s stock after buying an additional 3,904 shares during the quarter. Zhang Financial LLC’s holdings in Gilead Sciences were worth $1,086,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Cetera Investment Advisers lifted its position in shares of Gilead Sciences by 9.2% in the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after acquiring an additional 4,877 shares during the period. Baird Financial Group Inc. lifted its position in shares of Gilead Sciences by 3.9% in the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock worth $26,660,000 after acquiring an additional 16,643 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 44.3% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 2,654 shares during the period. Donaldson Capital Management LLC lifted its position in shares of Gilead Sciences by 12.5% in the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 641 shares during the period. Finally, Ergoteles LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $2,304,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.9 %

NASDAQ GILD opened at $66.76 on Friday. The stock has a fifty day moving average of $71.96 and a 200-day moving average of $76.53. The stock has a market capitalization of $83.12 billion, a P/E ratio of 14.84, a price-to-earnings-growth ratio of 0.91 and a beta of 0.19. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business posted $1.67 earnings per share. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.61%. Gilead Sciences’s payout ratio is 68.44%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Finally, Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $84.71.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.